Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line

Chinese Medical Journal

Volumn 121, Issue 16, 2008, Pages 1563-1568

  Gao, Jian Hua ^a   He, Zhi Juan ^a   Wang, Qi ^a   Li, Xin ^b   Li, Yi Xuan ^b   Liu, Min ^b   Zheng, Jian Hua ^a   Tang, Hua ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Calcium binding proteins; Drug resistance; Ovarian cancer; Paclitaxel

Indexed keywords

PACLITAXEL; PROTEIN S 100; SMALL INTERFERING RNA; TETRAZOLIUM;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 52949126287     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200808020-00012     Document Type: Article

References (22)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
2. Gribenko A, Lopez MM, Richardson JM, III, Makhatadze GI. Cloning, overexpression, purification, and spectroscopic characterization of human S100P. Protein Sci 1998; 7: 211-215.
3. Gribenko AV, Hopper JE, Makhatadze GI. Molecular characterization and tissue distribution of a novel member of the S100 family of EF-hand proteins. Biochemistry 2001; 40: 15538-15548.
4. 2+ binding properties. Eur J Biochem 1992; 207: 541-547.
5. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, Hansen M, Eloranta JJ, Bhakta V, et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer Am J Pathol 2005; 166: 81-92.
6. Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007; 31: 673-680.
7. Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, Chang TC, et al. Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer 2006; 119: 91-98.
8. Arumugam T, Simeone DM, Van GK, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 2005; 11: 5356-5364.
9. Tang H, Liu YJ, Liu M, Li X. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP. Anticancer Drugs 2007; 18: 633-639.
10. Semizarov D, Kroeger P, Fesik S. siRNA-mediated gene silencing: a global genome view. Nucleic Acids Res 2004; 32: 3836-3945.
11. Martin SE, Caplen NJ. Applications of RNA interference in mammalian systems. Annu Rev Genomics Hum Genet 2007; 8: 81-108.
12. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; 14: 195-208.
13. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003; 3: 1-19.
14. Tanino T, Nawa A, Kondo E, Kikkawa F, Daikoku T, Tsurumi T, et al. Paclitaxel-2′-Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity. Pharm Res 2007; 24: 555-565.
15. Pan L, Tong Y, Jin Y, Zhou S, Zhang Y, Yang X, et al. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides. Chin Med J 2001; 114: 929-932.
16. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, et al. Identification of genes with differential expression in acquired drug resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 2004; 10: 272-284.
17. Bertram J, Palfner K, Hiddemann W, Kneba M. Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs 1998; 9: 311-317.
18. Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE, Simm A. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 2007; 43: 1935-1943.
19. Beissel B, Silva ID, Posquero JB, Russo J, Schor N, Bellini MH. S-phase reduction in T47D human breast cancer epithelial cells induced by an S100P antisense-retroviral construct. Oncol Rep 2007; 17: 611-615.
20. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006; 98: 1806-1818.
21. 2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol Biol Cell 2003; 14: 2372-2384.
22. Filipek A, Jastrzebska B, Nowotny M, Kuznicki J. CacyBP/SIP, a calcyclin and Siah-1-interß-acting protein, binds EF-hand proteins of the S100 family, J Biol Chem 2002; 277: 28848-28852.